We have demonstrated that inhibition of SHP2 converts triple-negative breast cancer cells into hormone-positive (ERα-positive) cells that depend on estrogen signaling for growth (Figure 5A and B). This evidence concerns the gene ESR1 and triple-negative breast carcinoma.